| DBV Stock | | | EUR 0.65 0.05 8.33% |
Executive
Mr. Hugh A. Sampson, M.D., is an Chief Scientific Officer of the Company. effective on November 1, 2015. Hugh A. Sampson, M.D., is a professor of Pediatrics at the Icahn School of Medicine at Mount Sinai School, N.Y., USA. He is Director of the Jaffe Food Allergy Institute and Dean of Translational Biomedical Science at The Mount Sinai Medical Center. He received his M.D. from the State University of New York at Buffalo School of Medicine. Dr. Sampson research interests have focused on food allergic disorders, including work on the immunopathogenic role of food hypersensitivity in atopic dermatitis, the pathogenesis of foodinduced anaphylaxis, the characterization of foodinduced gastrointestinal hypersensitivities, the characterization of food allergens, and novel immunotherapeutic strategies for treating food allergies. His research was funded by a number of grants from the National Institutes of Health and private foundations. He is the Principal Investigator of the NIHsponsored Consortium of Food Allergy Research . He is also former President of the American Academy of Allergy Asthma and Immunology . since 2015.
| Age | 70 |
| Tenure | 9 years |
| Phone | 33 1 55 42 78 78 |
| Web | https://www.dbv-technologies.com |
DBV Technologies Management Efficiency
The company has return on total asset
(ROA) of
(0.2178) % which means that it has lost $0.2178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.4299) %, meaning that it generated substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.
DBV Technologies SA has accumulated 12.8
M in total debt with debt to equity ratio
(D/E) of 0.09, which may suggest the company is not taking enough advantage from borrowing. DBV Technologies has a current ratio of 3.51, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist DBV Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, DBV Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like DBV Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for DBV to invest in growth at high rates of return. When we think about DBV Technologies' use of debt, we should always consider it together with cash and equity.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. DBV TECHNOLOGIES operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 97 people. DBV Technologies SA (DBV) is traded on Euronext Paris in France and employs 85 people.
Management Performance
DBV Technologies Leadership Team
Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wence Agbotounou, Chief Clinical Trial Officer | |
| Viviane Monges, Non-Executive Independent Director | |
| Caroline Daniere, Chief Human Resource Officer | |
| Claire Giraut, Non-Executive Independent Director | |
| Adam Slatter, Chief Quality Officer | |
| Daniel Tass, CEO Director | |
| Daniel Soland, Non-Executive Independent Director | |
| Julie ONeill, Non-Executive Director | |
| Hugh Sampson, Chief Scientific Officer | |
| Pascal Wotling, Chief Technical Operations Officer | |
| Ramzi Benamar, Chief Financial Officer | |
| Lucie Mondoulet, Director of Research | |
| Anne Pollak, Head Relations | |
| Michele Robertson, Chief Legal Officer | |
| MarieCatherine Therene, Deputy Chief Executive Officer and Responsible Pharmacist | |
| Joseph Becker, VP Communications | |
| Sbastien Robitaille, Chief Officer | |
| Daniel Tasse, Chief Executive Officer, Director | |
| Michael Goller, Non-Executive Director | |
| Sebastien Robitaille, Chief Financial Officer | |
| Torbjorn Bjerke, Non-Executive Independent Director | |
| Pharis Mohideen, Chief Medical Officer | |
| Kevin Trapp, Chief Commercial Officer | |
| Mailys Ferrere, Non-Executive Director | |
| Michel Rosen, Non-Executive Independent Chairman of the Board | |
DBV Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in DBV Stock
DBV Technologies financial ratios help investors to determine whether DBV Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DBV with respect to the benefits of owning DBV Technologies security.